8-K: Tevogen Bio Stockholders Approve Incentive Plan Boost, Reverse Split

Tevogen Bio Holdings Inc. stockholders approved a significant increase in shares for its incentive plan and authorized a reverse stock split to be implemented at the Board's discretion.

Summary

• Stockholders of Tevogen Bio Holdings Inc. held a Special Meeting on February 19, 2026.
• Approved an amendment to the 2024 Omnibus Incentive Plan, increasing the number of shares available for issuance thereunder by 100,000,000 shares.
• The Plan now allows for a total of 140,000,000 shares (Initial Share Limit) plus annual increases of up to 5.0% of outstanding shares for ten years, starting in 2025, in addition to the newly approved 100,000,000 shares.
• Approved an amendment to the Certificate of Incorporation to effect a reverse stock split of the common stock at a ratio between 1:25 and 1:85, with the exact ratio and timing to be determined by the Board in its sole discretion.
• On the record date of January 21, 2026, 201,522,282 shares of Common Stock were issued and outstanding.
• A total of 182,412,517 shares were present at the Special Meeting (in person virtually or represented by valid proxy).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the approval of a reverse stock split, which often signals underlying stock performance issues, despite the positive aspect of expanding the employee incentive plan.

Positives

• Stockholder approval of the 2024 Omnibus Incentive Plan amendment provides additional shares for employee compensation, potentially enhancing talent attraction and retention.

Negatives

• The approval of a reverse stock split, typically considered when a company's stock price is low, often signals underlying financial challenges or concerns about meeting exchange listing requirements.
• A reverse stock split can sometimes lead to decreased liquidity and further price declines post-split.

Risks

• A reverse stock split carries the risk of further stock price decline and reduced trading liquidity.
• The increased share pool for the incentive plan, while beneficial for employees, could lead to future dilution for existing shareholders.

Future Outlook

The Board of Directors has the sole discretion to determine the exact ratio (between 1:25 and 1:85) and the timing, if at all, of the approved reverse stock split. Upon effectiveness of any such reverse stock split, the number of shares reserved for issuance under the 2024 Plan, including those added by the Plan Amendment, and the number of shares of Common Stock subject to outstanding awards under the 2024 Plan will be adjusted in proportion to the ratio of the reverse stock split.

Management Comments

• The Company has caused its authorized officer to execute this Amendment to the Plan. (Referring to Kirti Desai, CFO, signing the amendment)
• Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Referring to Ryan Saadi, CEO, signing the 8-K)

Industry Context

StockSavvy.ai notes that reverse stock splits are often utilized by companies, particularly in the biotechnology sector, to increase their share price to meet minimum listing requirements of exchanges like Nasdaq, or to make their stock more attractive to institutional investors. While it doesn't change the company's market capitalization, it can be perceived negatively by the market as a sign of distress. The simultaneous increase in an incentive plan share pool is common for growth-oriented companies to attract and retain talent.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the increased incentive plan share pool; impact on stock price and liquidity due to the reverse stock split.
• Employees: Benefit from increased shares available for equity-based compensation under the 2024 Omnibus Incentive Plan.

Next Steps

• The Board of Directors will determine the exact ratio (between 1:25 and 1:85) and the timing, if at all, of the reverse stock split.
• Upon effectiveness of any reverse stock split, the number of shares reserved for issuance under the 2024 Plan and outstanding awards will be adjusted proportionally.

Key Dates

Recommendation

The approval of a reverse stock split, particularly with a wide potential ratio range (1:25 to 1:85), is a strong indicator of significant stock price underperformance and often signals a company struggling to maintain exchange listing requirements. While the incentive plan expansion is positive for employee retention, the overarching signal from the reverse split is negative, suggesting fundamental issues that could lead to further share price erosion and reduced investor confidence. A seasoned investor would likely view this as a signal to exit or significantly reduce exposure.

Keywords

Tevogen Bio, TVGN, SEC Filing, 8-K, Reverse Stock Split, Omnibus Incentive Plan, Shareholder Meeting, Corporate Governance, Stock Compensation, Nasdaq Listing